Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase.
The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02890368
Contact: Theresa Thompson email@example.com
Contact: Yaping Shou, MD, PhD Yaping@trilliumtherapeutics.com
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Recruiting
New York, New York, United States, 10016
Contact: Angela Tan 646-501-7869 Angela.Tan@nyumc.org
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Alexander Lesokhin firstname.lastname@example.org